Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ginseng meetings

This article was originally published in The Tan Sheet

Executive Summary

The Department of the Interior's Fish & Wildlife Service will host three public meetings to collect comment on American ginseng, according to a notice in the Federal Register Dec. 29. The findings will be used to gather information for the agency's 2006 findings on the export of American ginseng roots, for the issuance of permits under the Convention on International Trade in Endangered Species of Wild Fauna & Flora (CITES). The Fish & Wildlife Service changed the legal age for export of American ginseng from a five-year old plant to a 10-year old plant in August, which prompted industry members such as the American Herbal Products Association to voice concerns about the rule's economic effect on harvesters (1"The Tan Sheet" Aug. 15, 2005, p. 12). The meetings will be held in Moon Township, Penn. Jan. 31, Asheville, N.C. Feb. 10 and Indianapolis, Ind. Feb. 15...

You may also be interested in...



Ginseng Export Finding May Cause “Significant” Drop In Wild Harvest – AHPA

The U.S. Department of Interior Fish & Wildlife Services' finding on the export of whole wild American ginseng will affect the entire whole-plant ginseng harvest for the next five years, says the American Herbal Products Association

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098984

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel